Santacruzamate A

A highly potent and selective inhibitor of HDAC2 isolated from the Panamanian marine cyanobacterium cf. Symploca (IC50=0.119 and 434 nM for HDAC2 and HDAC6 respectively). Induces apoptosis and cancer cell death only in combination with other HDAC1 inhibitors. Potential therapeutic agent for breast cancer. Attenuates Aβ fragment (Aβ25-35)-induced toxicity in PC12 cells by enhancing ER stress tolerance. Ameliorates Alzheimer’s disease-like pathology in mouse models.